Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Cagrilintide

AM-833, Long-acting amylin analogue

Quick Stats
Studies 57
Trials 38
Active Not Recruiting PHASE3 INTERVENTIONAL NCT07011667

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.

Interventions

Name: CagriSema (Cagrilintide B and Semaglutide I)
Type: DRUG
Description: CagriSema (Cagrilintide B and Semaglutide I) will be administered subcutaneously using DV3384 pen-injector.
Name: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Type: DRUG
Description: Placebo matched to Cagrilintide B and placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

Primary Outcomes

Measure: Relative change in body weight
TimeFrame: From baseline (week 0) to week 80
Description: Measured as percentage change.

Trial Information

NCT ID

NCT07011667

Status

Active Not Recruiting

Study Type

INTERVENTIONAL

Phases

PHASE3

Sponsor

Novo Nordisk A/S

Last Updated

December 15, 2025